Home › Research › Topics › plasma-phosphorylated
plasma-phosphorylated
5 studies tagged plasma-phosphorylated, dated 2021-10-14 to 2022-12-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Plasma phosphorylated tau181 predicts cognitive and functional decline 2022-12-14
- Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy 2022-10-01
- Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients 2022-09-08
Studies
5 studies carry this tag.
Date range
2021 to 2022
Top journals
- Alzheimer's & dementia (Amsterdam, Netherlands) 1
- Annals of clinical and translational neurology 1
- Annals of neurology 1
- Brain : a journal of neurology 1
- CNS neuroscience & therapeutics 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Plasma p-tau181 differentiates AD pathology cases from NC with high accuracy.
-
Blood-based biomarkers such as tau phosphorylated at threonine 181 (phosphorylated-tau181) represent an accessible, cost-effective and scalable approach for the in vivo detection of Alzheimer's disease pathophysiology.
-
Our findings highlight that plasma p-tau181, alone or combined with NfL, contributes to identifying high-risk AD populations.
-
We found strong evidence that plasma p-tau 181 is elevated in ALS and may be a novel marker specific to LMN dysfunction.
-
Despite assumptions that cognitive changes invariably follow biomarker changes, early neuropsychological difficulties may emerge before/concurrently with plasma p-tau181 changes.